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ABSTRACTS INTRODUCTION
Welcome to the 2nd European Lung Cancer Conference
On behalf of The European Society for Medical Oncology(ESMO) and the International Association for the Study
of Lung Cancer (IASLC), it gives us great pleasure to
welcome you to the 2nd European Lung Cancer Conference,
28 April–1 May 2010 in Geneva, Switzerland.
After a very successful inaugural Conference in 2008,
both Societies agreed that a regular scientific and educational
meeting in this area is important for providing a comprehen-
sive overview of the most significant advances in lung cancer
research and treatment. Over the past few years, molecular
biology has revolutionized everything we have ever known
about the natural history of this illness. Treatment must be
approached by multiple specialists and the strategy must be
tailored for every patient. As such attendees at this Confer-
ence will be joined by leading specialists from different
latitudes of the world in order to exchange knowledge and
experience.
The program has interactive formats, which include
debates on controversial topics, educational and keynote
lectures, meet the expert sessions and specialty-specific
workshops. Attendance at this 2nd European Lung Cancer
Conference will be a rewarding experience in enhancing
positive interactions between all lung cancer-related disci-
plines. The Scientific Committee is delighted to be in a
position to encourage poster sessions and discussions and oral
presentations on perspectives, ideas, results and research
solutions submitted to promote an integrated approach to
diagnosis and treatment of lung cancer.
In addition to the high quality scientific presentations,
the Committee introduced several improvements to the Con-
ference program, with the aim of providing a comprehensive
overview necessary for clinicians to fully understand how to
utilize and interpret advances in various molecular, genetic,
pharmacogenomic, pathology and imaging methods and as-
sessments; ensuring that the latest best practices and valuable
key points/messages presented by the faculty can be put into
clinical practice today. Our aim is to deliver an outstanding
program with the right balance of clinical relevance, so an
important part of the program covers the entire spectrum of
practice issues in lung cancer.
The Conference will discuss current trends in surgical,
radiotherapeutic and chemotherapeutic approaches to lung
cancer with ongoing focus on the individualization of therapy
based on clinical, histologic and molecular characteristics.
The Conference format is designed to enhance discussion
about early stages of lung cancer from the aspect of different
potential treatments and combined modalities with specific
questions about the role of surgery. The program also high-
lights the role of radiation in lung cancer treatment and the
formidable development of new techniques such as stereo-
tactic body, image-guided and intensity-modulated radiation
therapy. The Conference will also feature presentations on
optimizing the application of established targeted agents as
well as presentations introducing emerging targeted agents,
including mechanisms of action and preclinical/clinical re-
sults.
We trust that participants will highly value the scope
and depth of the information on tumor biology, pathology,
prevention, early detection, epidemiology, tobacco control,
imaging, staging, management-related issues and transla-
tional and clinical research, presented with the emphasis on
interdisciplinary challenges and supported by clinical inter-
pretations needed for application of recent studies.
Our sincere thanks go to the members of the scientific
committee, invited speakers, Conference organizers and
sponsors for their commitment to this Conference. We hope
that you enjoy the meeting and will already make a note in
your diary for the 3rd edition in 2012.
Franc¸oise Mornex and Rafael Rosell
Scientific Committee Co-Chairs
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